Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Observational studies have reported a high prevalence of obesity and diabetes in subjects on methadone therapy; there are, however, limited data about metabolic syndrome. The aim of the study was to evaluate the prevalence of metabolic syndrome and related factors in individuals with heroin use disorder on methadone therapy. Methods: A cross-sectional study in individuals with heroin use disorder on methadone therapy at a drug abuse outpatient center. Medical examinations and laboratory analyses after a 12-hour overnight fast were recorded. Metabolic syndrome was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (ATP III) criteria. Results: One hundred and twenty-two subjects were included, with a mean age of 46.1 ± 9 years, a median body mass index (BMI) of 25.3 kg/m 2 (interquartile range [IQR]: 21.2–28), and 77.9% were men. Median exposure to methadone therapy was 13 years (IQR: 5–20). Overweight and obesity were present in 29.5% and 17.2% of the participants, respectively. Metabolic syndrome components were low high-density lipoprotein (HDL) cholesterol (51.6%), hypertriglyceridemia (36.8%), high blood pressure (36.8%), abdominal obesity (27.0%), and raised blood glucose levels (18.0%). Abdominal obesity was more prevalent in women (52% vs. 20%, P = >0.01) and high blood pressure more prevalent in men (41.1% vs. 22.2%, P = .07). Prevalence of metabolic syndrome was 29.5% (95% confidence interval [CI]: 16.6–31.8). In the multivariate logistic regression analysis, BMI (per 1 kg/m 2 increase odds ratio [OR]: 1.49, 95% CI: 1.27–1.76) and exposure time to methadone therapy (per 5 years of treatment increase OR: 1.38, 95% CI: 1.28–1.48) were associated with metabolic syndrome. Conclusions: Overweight and metabolic syndrome are prevalent findings in individuals with heroin use disorder on methadone therapy. Of specific concern is the association of methadone exposure with metabolic syndrome. Preventive measures and clinical routine screening should be recommended to prevent metabolic syndrome in subjects on methadone therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2074 · Cited by 1,025
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566
Substance use disorder among older adults in the United States in 2020
Han, B., Gfroerer, J. C., Colliver, J. D., & Penne, M. A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02411.x · Cited by 337
Nolan, L. J., & Scagnelli, L. M. (2007) · Substance Use & Misuse · doi:10.1080/10826080701517727 · Cited by 106
Increases in body mass index following initiation of methadone treatment
Fenn, J. M., Laurent, J. S., & Sigmon, S. C. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.10.007 · Cited by 62
Risk factors for weight gain during methadone maintenance treatment
Peles, E., Schreiber, S., Sason, A., & Adelson, M. (2016) · Substance Abuse · doi:10.1080/08897077.2016.1179705 · Cited by 59
Cited by
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566
Nutritional implications of opioid use disorder: A guide for drug treatment providers
Chavez, M. N., & Rigg, K. K. (2020) · Psychology of Addictive Behaviors · doi:10.1037/adb0000575 · Cited by 38
Metadata
- Authors
- Vallecillo, G., Robles, M. J., Torrens, M., Samos, P., Roquer, A., Martires, P. K., Sanvisens, A., Muga, R., & Pedro-Botet, J.
- Venue
- Substance Abuse
- Publisher
- SAGE Publications
- Published
- 2018-01
- Volume
- 39
- Issue
- 1
- Pages
- 46-51
- ISSN
- 0889-7077 (ISSN-L)
- 1547-0164
- OpenAlex
- W2743388190
- Cited by
- 42
- References
- 6
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors. https://app.cochat.ai/papers/10.1080/08897077.2017.1363122
- The paper
- Vallecillo, G., Robles, M. J., Torrens, M., Samos, P., Roquer, A., Martires, P. K., Sanvisens, A., Muga, R., & Pedro-Botet, J. (2018). Metabolic Syndrome among Individuals with Heroin use Disorders on Methadone Therapy: Prevalence, Characteristics, and Related Factors. Substance Abuse. https://doi.org/10.1080/08897077.2017.1363122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.